Brief: Sino Biopharmaceutical's Kras G12c Inhibitor Included In Breakthrough Therapeutic Designation
11/06/2024 11:47
June 11 (Reuters) - Sino Biopharmaceutical Ltd
1177.HK :
* KRAS G12C INHIBITOR "GARSORASIB TABLET (D-1553)" INCLUDED
IN
BREAKTHROUGH THERAPEUTIC DESIGNATION PROCESS OF NMPA
Source text for Eikon: ID:n11244976-1
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsBrief: Sino Biopharmaceutical Announces Share Purchase Plan For HK$2 Billion
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up